Doripenem: A new carbapenem in the treatment of nosocomial infection

Clinical Infectious Diseases

Volumn 49, Issue SUPPL. 1, 2009, Pages

  Mandell, Lionel ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; DORIPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECONOMIC ASPECT; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INFECTION RISK; NEUROTOXICITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEIZURE; SHORT SURVEY; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

BETA-LACTAMASES; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; HUMANS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 67749101888     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599809     Document Type: Short Survey

References (11)

1. Rahal JJ. Antimicrobial resistance among and therapeutic options against gram-negative pathogens. Clin Infect Dis 2009; 49(Suppl 1): S4-10 (in this supplement).
2. Kollef MH. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respir Care 2004; 49:1530-1541
3. Sahm D. The in vitro activity of doripenem. Clin Infect Dis 2009; 49(Suppl 1):S11-16 (in this supplement).
4. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48:3086-3092
5. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot (Tokyo) 2006; 59:220-228
6. Restrepo MI. The efficacy of intravenous infusion of doripenem. Clin Infect Dis 2009; 49(Suppl 1):S17-27 (in this supplement).
7. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089-1096
8. Chastre J, Jiang J, Kaniga K, Friedland I. Efficacy of doripenem against Pseudomonas aeruginosa in nosocomial pneumonia, including ventilator-associated pneumonia [poster P 556]. In: Program and abstracts of the 18th European Congress of Clinical Microbiology and Infectious Diseases (Barcelona, Spain). 2004.
9. Redman R, File T. Safety of intravenous infusion of doripenem. Clin Infect Dis 2009; 49(Suppl 1):S28-35 (in this supplement).
10. Amin A. Clinical and economic consequences of ventilator-associated pneumonia. Clin Infect Dis 2009; 49(Suppl 1):S36-43 (in this supplement).
11. Merchant S, Gast C, Nathwani D, et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008; 30:717-733 (Pubitemid 351680488)